FDA’s May 20, 2026 warning letters and Luna G3/G3X: what the supplied evidence can and cannot establish

The essential distinction

The verified evidence supplied for this article does not contain either described May 20, 2026 warning letter. Consequently, it cannot verify the letters’ wording, findings, affected products or serial numbers, company responses, or regulatory status.

In particular, the supplied documents do not verify claims involving Luna G3 APAP firmware G3-2.00.76, unexpected shutdown or loss of therapy, a firmware correction, G3X APAP design changes, complaint handling, software-risk management, or iCodeConnect. This does not establish that such FDA statements do not exist; it means they cannot be confirmed from the verified material provided here.

What the available FDA record actually says

FDA’s 510(k) database identifies K153387 as the “Luna CPAP and Auto CPAP System,” submitted by 3B Medical, Inc. FDA recorded a substantially equivalent decision on September 8, 2016, and classified the product as a non-continuous ventilator under regulation 21 CFR 868.5905. [1]

That database entry is a 510(k) premarket-notification record. It does not mention Luna G3, G3X, firmware G3-2.00.76, React Health, or iCodeConnect in the supplied text. [1]

Does the evidence show a product recall?

No recall is established by the supplied evidence. The available FDA entry documents the 2016 510(k) decision for the Luna CPAP and Auto CPAP System. It is not an FDA recall entry. [1]

The record also does not support a claim that all Luna devices are affected. It contains no affected-model, firmware, lot, or serial-number range and provides no information about later Luna G3 or G3X configurations. [1]

What the evidence says about PAP therapy

APAP automatically adjusts the air pressure delivered during sleep, while CPAP provides constant air pressure through the mouth and/or nose to help keep the airways open and support breathing during sleep. The National Heart, Lung, and Blood Institute describes a PAP machine as the most common treatment for sleep apnea and advises patients to talk to their healthcare provider about which type is most appropriate. [2]

The American Academy of Sleep Medicine states that PAP treatment should be based on an obstructive sleep apnea diagnosis established through objective testing and that adequate follow-up should occur after PAP initiation and during treatment. Its guideline recommends either CPAP or APAP for ongoing treatment of obstructive sleep apnea in adults. [3]

What Luna users can and cannot conclude

• The supplied FDA record concerns an earlier named system. It identifies the Luna CPAP and Auto CPAP System but does not mention Luna G3 or G3X. [1]
• The alleged 2026 findings are not verified here. The supplied evidence does not establish the warning letters’ wording, scope, response deadlines, affected products, or enforcement status.
• A brand-wide problem is not established. The available FDA record contains no verified affected-model, firmware, lot, or serial-number range. [1]
• PAP care should remain clinician-guided. Patients can discuss concerns about their PAP treatment with their healthcare provider, and adequate follow-up should occur during treatment. [2][3]

What remains unresolved

Based solely on the supplied evidence, no conclusion can be reached about whether FDA made the described observations, whether any company corrected or disputed them, whether FDA later closed any matter, or whether additional regulatory action followed. The verified material provided here does not address those questions.

Bottom line: the only verified FDA device record provided is the 2016 510(k) clearance for the Luna CPAP and Auto CPAP System. It does not verify the described May 20, 2026 findings and does not establish a recall, a final enforcement outcome, or a problem affecting every Luna device. [1]

This article provides general educational information and is not medical advice. Do not start, stop, or change CPAP therapy or settings without guidance from a qualified clinician.

Sources

1. [1] 510(k) Premarket Notification K153387: Luna CPAP and Auto CPAP System — U.S. Food and Drug Administration
2. [2] Sleep Apnea Treatment — National Heart, Lung, and Blood Institute
3. [3] Clinical practice guideline on PAP therapy for sleep apnea — American Academy of Sleep Medicine